Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Drug Toxicity
Questions discussed in this category
What, if any, cardioprotective measures beyond dexrazoxane may be used to minimize cardiac risk during or after chemo- or radio-therapy?
Are there other measures, pharmocologic or adjunctive, that can be used or are under investigation to mitigate cardiotoxicity related to chemo- or rad...
2 Answers available
Is it safe to give large fraction stereotactic irradiation for brain metastases concurrently with VEGF inhibitors?
0 Answers available
How do you integrate ophthalmic exam and surveillance into routine visits for cervical cancer patients receiving tisotumab vedotin?
2 Answers available
19100
12794
12002
Papers discussed in this category
Eur Heart J, 2022 Nov 01
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
JACC. Heart failure, 2022 Jun 08
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
JAMA, 2023 Aug 8
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Cardio-oncology (London, England), 2021 Sep 27
Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial.
JACC. CardioOncology, 2023 Jun 20
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: Primer.
Related Topics
Medical Oncology
Radiation Oncology
Gynecologic Cancers
Cervical Cancer
Supportive Care
Ophthalmology
Palliation
Neuro-Oncology
CNS Disease
Dermatology